135 related articles for article (PubMed ID: 36032981)
1. Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape.
Witte L; Baharani V; Schmidt F; Wang Z; Cho A; Raspe R; Guzman-Cardozo MC; Muecksch F; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
bioRxiv; 2022 Aug; ():. PubMed ID: 36032981
[TBL] [Abstract][Full Text] [Related]
2. Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape.
Witte L; Baharani VA; Schmidt F; Wang Z; Cho A; Raspe R; Guzman-Cardozo C; Muecksch F; Canis M; Park DJ; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Nat Commun; 2023 Jan; 14(1):302. PubMed ID: 36653360
[TBL] [Abstract][Full Text] [Related]
3. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
4. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
5. Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice.
Lu RM; Liang KH; Chiang HL; Hsu FF; Lin HT; Chen WY; Ke FY; Kumari M; Chou YC; Tao MH; Yi-Ling Lin ; Wu HC
Heliyon; 2023 May; 9(5):e15587. PubMed ID: 37090428
[TBL] [Abstract][Full Text] [Related]
6. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
7. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
Cameroni E; Saliba C; Bowen JE; Rosen LE; Culap K; Pinto D; VanBlargan LA; De Marco A; Zepeda SK; Iulio JD; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà P; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Veesler D; Snell G; Corti D
bioRxiv; 2021 Dec; ():. PubMed ID: 34931194
[TBL] [Abstract][Full Text] [Related]
8. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.
Huang M; Wu L; Zheng A; Xie Y; He Q; Rong X; Han P; Du P; Han P; Zhang Z; Zhao R; Jia Y; Li L; Bai B; Hu Z; Hu S; Niu S; Hu Y; Liu H; Liu B; Cui K; Li W; Zhao X; Liu K; Qi J; Wang Q; Gao GF
Immunity; 2022 Aug; 55(8):1501-1514.e3. PubMed ID: 35777362
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
10. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
Gruell H; Vanshylla K; Korenkov M; Tober-Lau P; Zehner M; Münn F; Janicki H; Augustin M; Schommers P; Sander LE; Kurth F; Kreer C; Klein F
Cell Host Microbe; 2022 Sep; 30(9):1231-1241.e6. PubMed ID: 35921836
[TBL] [Abstract][Full Text] [Related]
12. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
[TBL] [Abstract][Full Text] [Related]
14. Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
Planchais C; Fernández I; Bruel T; de Melo GD; Prot M; Beretta M; Guardado-Calvo P; Dufloo J; Molinos-Albert LM; Backovic M; Chiaravalli J; Giraud E; Vesin B; Conquet L; Grzelak L; Planas D; Staropoli I; Guivel-Benhassine F; Hieu T; Boullé M; Cervantes-Gonzalez M; Ungeheuer MN; Charneau P; van der Werf S; Agou F; ; ; Dimitrov JD; Simon-Lorière E; Bourhy H; Montagutelli X; Rey FA; Schwartz O; Mouquet H
J Exp Med; 2022 Jul; 219(7):. PubMed ID: 35704748
[TBL] [Abstract][Full Text] [Related]
15. Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages.
Ren P; Hu Y; Peng L; Yang L; Suzuki K; Fang Z; Bai M; Zhou L; Feng Y; Zou Y; Xiong Y; Chen S
bioRxiv; 2023 Mar; ():. PubMed ID: 35982661
[TBL] [Abstract][Full Text] [Related]
16. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Landau NR; Tada T
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746806
[TBL] [Abstract][Full Text] [Related]
17. BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants.
Rössler A; Netzl A; Knabl L; Schäfer H; Wilks SH; Bante D; Falkensammer B; Borena W; von Laer D; Smith DJ; Kimpel J
Nat Commun; 2022 Dec; 13(1):7701. PubMed ID: 36513653
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern.
Facciuolo A; Van Kessel J; Kroeker A; Liao M; Lew JM; Falzarano D; Kelvin AA; Gerdts V; Napper S
Front Microbiol; 2023; 14():1148255. PubMed ID: 37065160
[TBL] [Abstract][Full Text] [Related]
19. IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2.
Nikitin PA; DiMuzio JM; Dowling JP; Patel NB; Bingaman-Steele JL; Heimbach BC; Henriquez N; Nicolescu C; Polley A; Sikorski EL; Howanski RJ; Nath M; Shukla H; Scheaffer SM; Finn JP; Liang LF; Smith T; Storm N; McKay LGA; Johnson RI; Malsick LE; Honko AN; Griffiths A; Diamond MS; Sarma P; Geising DH; Morin MJ; Robinson MK
Sci Immunol; 2022 Sep; 7(75):eabl9943. PubMed ID: 35771946
[TBL] [Abstract][Full Text] [Related]
20. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JCC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
bioRxiv; 2020 Jul; ():. PubMed ID: 32743579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]